TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

Inclusion Criteria: * Clinical features of Huntington's disease (HD) and confirmatory family history of HD, and/or CAG repeat expansion greater than or equal to 36 * Ambulatory, not requiring skilled nursing care (total functional capacity \[TFC\] greater than or equal to 7) * Chorea score of at least 2 in one extremity (UHDRS) * Maximal dystonia less than or equal to 2 and maximal bradykinesia less than or equal to 2 * 35 years of age or older of either gender * Must be on stable dosages of non-competitive NMDA receptor antagonists, and/or antiepileptic medications for 60 days prior to baseline * Females of child-bearing potential must use adequate birth control Exclusion Criteria: * History of established diagnosis of tardive dyskinesia * Clinical evidence of unstable medical or psychiatric illness * Clinically significant active and unstable psychotic disease (hallucinations or delusions) * Major depression (Beck Depression Inventory \[BDI\]-II Score greater than 20) at Screening Visit * Suicidal ideation (BDI-II item 9 greater than or equal to 2) at Screening Visit * History of clinically significant substance abuse within 12 months of Baseline Visit * Pregnant/lactating women * Participation in other drug studies within 60 days prior to Baseline Visit * Previous participation in any investigational study of ethyl-EPA (Miraxion™) * Use of aspirin at daily dosage greater than 325 mg/day * Exclusionary Drugs (within 6 months Baseline Visit): Depot neuroleptics * Exclusionary Drugs (within 60 days Baseline Visit): Omega-3 supplementation, tetrabenazine or reserpine, high dose and/or variable dose oral anti-psychotic medications, steroid (other than topical), selenium supplements greater than 55 mcg/day, lithium, benzodiazepines (except for low dose), anticoagulants